Welcome to the Horizon 2020 atherosclerosis research program website
The groups of Riksen, Joosten and Netea investigated the induction of trained immunity (innate immune memory) and the role of immune and metabolic pathways that result in epigenetic rewiring of cellular functional programs. Trained immunity is the key mechanism studied in REPROGRAM and proposed as a common diseases mechanism underlying atherosclerosis and rheumatoid arthritis. The study published in CELL
After a successful 1st REPROGRAM project year and most scientific work currently underway, an INFORMAL MEET-UP will be organized for all “YOUNG” REPROGRAM researchers at the 85th European Atherosclerosis Society congress held in Prague, Czech Republic (23-26 April, 2017). In REPROGRAM, 9 academic groups are involved that embed over 10 Postdoctoral researchers and 12 PhD students, all dedicated to the development of
Bekkering et al determined the optimal conditions for an in vitro experimental protocol of monocyte training using three of the most commonly used training stimuli from the literature: -glucan, BCG vaccine, and oxLDL. Although the effects of these three stimuli on trained immunity have been described before, this is the first time that the kinetics of this in vitro model have
On January 30, 2017, the 2nd Governing Council meeting took place in Munich. This meeting was convened by the Work package 2 leader (Esther Lutgens, Ludwig-Maximilians-Universität München) and hosted at the Hilton Conference center nearby Munich Airport. The consortium members widely discussed the detailed project activities and workplan (Work-Packages and Tasks) and the main objectives of the
On January 30, 2017, the 2nd REPROGRAM Governing Council meeting is organized in Munich, Germany. All consortium partners are invited. Beside progress presentations of each work package leader, networking and training activities are scheduled.
ERA-NET on Cardiovascular Diseases Joint Transnational Call for Proposals 2017 (JTC 2017): “Mechanisms of early atherosclerosis and/or plaque instability in Coronary Artery Disease” CVD research is not only a crucial area in health research overall, but could become an outstanding example of research driven innovation across Europe. An effective coordination of research at national
Efforts to reverse the pathologic consequences of vulnerable plaques are often stymied by the complex treatment resistant pro-inflammatory environment within the plaque. This suggests that pro-atherogenic stimuli, such as LDL cholesterol and high fat diets may impart longer lived signals on (innate) immune cells that persist even after reversing the pro-atherogenic stimuli. Recently, a series
Background: Increasing numbers of patients (up to 40 %) with rheumatoid arthritis (RA) achieve remission, yet it remains to be elucidated whether this also normalizes their cardiovascular risk. Short-term treatment with TNF inhibitors lowers arterial wall inflammation, but not to levels of healthy controls. We investigated whether RA patients in long-term remission are characterized by
Every year The Radboud Center for Infectious Diseases organizes the international symposium ‘Summer Frontiers of Science’ on a cutting edge subject in infection and immunology. www.radboudumc.nl/summerfrontiers The subject of ‘Systems Biology of Innate Immunity’ will cover novel aspects on functional genomics, epigenomics, transcriptomics, microbiome and immunometabolism, related to the understanding of innate immune responses.
The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.